原發(fā)性IgA腎病的治療研究進(jìn)展

打開文本圖片集

[Abstract] IgA Nephropathy （IgAN） is the most common primary glomerular disease worldwide，and its pathological mechanism revolves aroundthe binding of circulating immune complexes containing IgA to mesangial cels，leading tosecondaryglomerularinflammationandtubulointerstitial fibrosis.Foralong time，clinicaltherapy for IgAN has mainly focused on symptomatic supportive treatment and systemic application of glucocorticoids，but a considerable proportion of patients still progressto end-stage renal disease （ESRD）.With a deeper understanding of the pathogenesis of IgAN，new therapeutic targets and drugs are being developed，including blockadeof the endothelin system，targeted therapyof the intestinal mucosal immune systemand Bcels，and complement inhibition. This review provides an overview of current， recently approved，and emerging IgAN treatment methods.

[Keywords] IgA nephropathy Non-immunotherapy Immunosuppression Targeted therapy 'omplement

First-author'saddres：DepartmentofNephrology，Binzhou MedicalUniversityHospital，inzhot 56600，China

doi：10.3969/j.issn.1674-4985.2025.21.038

IgA腎?。↖gAnephropathy，IgAN）是全球最常見(jiàn)的原發(fā)性腎小球疾病，也是慢性腎臟?。╟hronickidney disease，CKD）和終末期腎臟?。╡nd-stagerenaldisease，ESRD）的主要原因之一。（剩余11905字）